Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
| Autor: | Del Campo, J.M. *, Roszak, A., Bidzinski, M., Ciuleanu, T.E., Hogberg, T., Wojtukiewicz, M.Z., Poveda, A., Boman, K., Westermann, A.M., Lebedinsky, C. |
|---|---|
| Zdroj: | In Annals of Oncology November 2009 20(11):1794-1802 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|